Why the study?
Do vasodilating beta-blockers have a better metabolic profile regarding glycaemic control than traditional beta-blockers in hypertensive patients with diabetes or metabolic syndrome?
Do vasodilating beta-blockers have a better metabolic profile regarding glycaemic control than traditional beta-blockers in hypertensive patients with diabetes or metabolic syndrome?
Newer vasodilating beta-blockers may be preferable to conventional beta-blockers in hypertensive patients with diabetes or metabolic syndrome due to a more favorable metabolic profile.
No takes yet. Share an insight, caveat, or question.
May support preferring vasodilating beta-blockers in diabetic hypertension; leaves open confirmation by randomized trials.
Pantelis Sarafidis (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: